Arcus Biosciences: Refusing To Let The TIGIT Story Die, And Finding Potential Niches In Huge Markets

Core Insights - Arcus Biosciences, Inc. (NYSE: RCUS) has been identified as a company that is "too cheap to ignore," indicating potential undervaluation in the market [1] Company Analysis - The author has a PhD in biochemistry and extensive experience in analyzing clinical trials and biotech companies, which adds credibility to the insights provided about Arcus Biosciences [1] - The focus is on educating investors about the scientific aspects of the biotech industry, emphasizing the importance of due diligence in investment decisions [1] Industry Context - The article highlights the challenges and complexities of investing in the biotech sector, particularly the need for a strong understanding of clinical trials and scientific principles [1]